Rodin Thinks Selective HDAC2 Inhibition Will Prove Better Therapeutic Approach To Alzheimer’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Epigenetics-focused company believes a selective HDAC2 inhibitor could provide a safe way to treat signs and symptoms of Alzheimer’s. Having raised $12.9 million in Series A funding, Rodin hopes to move from lead optimization to clinical development over the next 18 to 24 months.